南威軟件(603636.SH):二季度共收到6項發明專利證書
格隆匯7月1日丨南威軟件(603636.SH)公佈,2021年第二季度,公司及下屬子公司共收到了中華人民共和國國家知識產權局頒發的6項發明專利證書,分別為一種基於java平台的目標網站內容獲取方法,一種Web數據預加載方法及系統,一種路口車輛圖片採集系統的傳輸方法及傳輸系統,一種自動檢測方法、系統及終端設備,一種數據服務方法及數據服務裝置,一種數據交互的方法及終端。
截止目前,公司及下屬子公司共擁有57項發明專利、21項實用新型專利及25項外觀設計專利。上述發明專利取得不會對公司近期經營產生重大影響,但有利於發揮公司自主知識產權技術優勢,完善知識產權保護體系,形成持續創新機制,從而增強公司核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.